EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?

Adele Tulone, Grazia Pennisi, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Roberto Cannella iD, Francesco Mercurio, Salvatore Petta iD

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12556 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Adele Tulone und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sezione di Gastroenterologia, PROMISE, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Genetic Testing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD), with its steadily increasing prevalence, represents now a major problem in public health. A proper referral could benefit from tools allowing more precise risk stratification. To this end, in recent decades, several genetic variants that may help predict and refine the risk of development and progression of MASLD have been investigated. In this review, we aim to discuss the role genetics in MASLD plays in everyday clinical practice. We performed a comprehensive literature search of PubMed for relevant publications. Available evidence highlights the emergence of genetic‐based noninvasive algorithms for diagnosing fatty liver, metabolic dysfunction‐associated steatohepatitis, fibrosis progression and occurrence of liver‐related outcomes including hepatocellular carcinoma. Nevertheless, their accuracy is not optimal and application in everyday clinical practice remains challenging. Furthermore, susceptible genetic markers have recently become subjects of great scientific interest as therapeutic targets in precision medicine. In conclusion, decisional algorithms based on genetic testing in MASLD to facilitate the clinician decisions on management and treatment are under growing investigation and could benefit from artificial intelligence methodology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingHumansAlgorithmsLiver NeoplasmsCarcinoma, HepatocellularFatty LiverDisease ProgressionGenetic Predisposition to DiseaseNon-alcoholic Fatty Liver DiseaseLiver CirrhosisGenetic Markers

Stichwörter der Autor:innen

MASHMASLDPNPLA3geneticmetabolic dysfunction associated steatotic liver diseasesteatohepatitis

Substanzen

Genetic Markers

Autor:innen und Institutionen

  • Sezione di Gastroenterologia, PROMISE, University of Palermo, Palermo, Italy.
  • Dipartimento di Biomedicina, Neuroscienze e Diagnostica Avanzata (BIND), University of Palermo, Palermo, Italy.

ORCID-Profile: Roberto Cannella, Salvatore Petta

Zitieren

APA

Tulone, A., Pennisi, G., Ciccioli, C., Infantino, G., La Mantia, C., Cannella, R., Mercurio, F., & Petta, S. (2024). Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12556

Vancouver

Tulone A, Pennisi G, Ciccioli C, Infantino G, La Mantia C, Cannella R, et al. Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12556

BibTeX
@article{Tulone2024,
  author = {Tulone, Adele and Pennisi, Grazia and Ciccioli, Carlo and Infantino, Giuseppe and La Mantia, Claudia and Cannella, Roberto and Mercurio, Francesco and Petta, Salvatore},
  title = {Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12556}
}
Kostenlos starten →